Company news

Revolution Medicines, Inc. news in 2024

Revolution Medicines, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

December 4, 2024

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

December 2, 2024

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

December 1, 2024

Revolution Medicines Announces Commencement of Public Offering of Common Stock

December 1, 2024

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

November 26, 2024

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

November 5, 2024

Revolution Medicines to Participate in Upcoming Investor Conferences

November 4, 2024

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

October 29, 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

October 24, 2024

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

October 22, 2024

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

October 20, 2024

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

October 6, 2024

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

August 6, 2024

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

July 30, 2024

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

July 10, 2024

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

July 7, 2024

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

May 7, 2024

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

April 30, 2024

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

April 8, 2024

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

April 7, 2024

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

March 27, 2024

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

February 25, 2024

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

February 19, 2024

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

Calls in 2024

Decks in 2024